Clopidogrel, sold as the brandname Plavix among others, is an antiplatelet medication that is used to reduce the risk of heart disease and stroke in those at high risk. It is also used together with aspirin in heart attacks and following the placement of a coronary artery stent. It is taken by mouth.
Scope of the Report:Clopidogrel has remained, ever since its first approval in 1997, the antiplatelet therapy of choice among physicians for the treatment of patients with conditions such as acute coronary syndrome or percutaneous coronary intervention. The drug was the first thienopyridine to hit the market, which gave it an excellent head start over a number of drugs for these conditions that are either available in the market or are in clinical trials. As a result, the drug did not face much competition and has taken over the global market, with its array of application constantly expanding.
The substantial and high-level evidence gathered over the years support the use of Clopidogrel for reduction of mortality and morbidity patients with acute coronary syndrome, myocardial infarction, and a number of other indications. As a result, the drug has developed a formidable presence in the global market over the years. Moreover, the drugÕs relative ease of use, low rate of incidence of adverse reactions, and good tolerability have made it the de-facto antiplatelet agent for the reduction of atherosclerotic events in patients.
These factors have helped the global Clopidogrel market to tread along an excellent growth path in the past few years and the market is expected to embark upon a healthy growth path in the next few years as well. However, the overall profitability of the market has reduced to a certain extent owing to entry of a number of generic products post the patent expiry of Clopidogrel manufacture in 2013. Nevertheless, the vast pool of patients prescribed Clopidogrel on an annual basis across the globe will allow market players excellent growth prospects in the next few years.
The worldwide market for Clopidogrel is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2026, from xx million US$ in 2020, according to a new study.
This report focuses on the Clopidogrel in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers Sanofi (France)
Shenzhen Salubris Pharmaceuticals (China)
Lepu Medical Technology (China)
Market Segment by Regions, regional analysis covers North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers 25mg
75 mg
300 mg
Market Segment by Applications, can be divided into Hospitals
Private Clinics
Retail Pharmacies
Online Pharmacies
Others
There are 15 Chapters to deeply display the global Clopidogrel market.
Chapter 1, to describe Clopidogrel Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Clopidogrel, with sales, revenue, and price of Clopidogrel, in 2018 and 2019;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2018 and 2019;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Clopidogrel, for each region, from 2015 to 2020;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2015 to 2020;
Chapter 12, Clopidogrel market forecast, by regions, type and application, with sales and revenue, from 2020 to 2026;
Chapter 13, 14 and 15, to describe Clopidogrel sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
Frequently Asked Questions
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
- By Type
- By Application
- By Region
- By Country
- By Manufacturer
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.